5-iodo-N-methylisatoic anhydride | 151979-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 5-iodo-N-methylisatoic anhydride
• 英文别名: 6-iodo-1-methyl-1H-benzo[d][1,3]oxazine-2,4-dione；6-iodo-1-methyl-3,1-benzoxazine-2,4-dione
• CAS: 151979-22-5
• 化学式: C₉H₆INO₃
• 分子量: 303.056
• InChiKey: FZESGZQCRIEWET-UHFFFAOYSA-N

物化性质

• 沸点：
  390.4±44.0 °C(Predicted)
• 密度：
  1.975±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-iodo-N-methylisatoic anhydride 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold

  摘要：

  Earlier studies of peptides containing the arginine-glycine-aspartic acid (RGD) sequence led to the development of a structural model describing the three-dimensional presentation required for RGD-mediated inhibition of glycoprotein IIbIIIa/fibrinogen binding. We describe here the use of that structural model to design a rigid, non-peptidal lead series that reproduces the topography of the peptide backbone using a benzodiazepinedione scaffold. This scaffold is used to synthesize novel molecules which are highly potent inhibitors of platelet aggregation and which possess improved bioavailability. The importance of shape as a design criterion is demonstrated by constructing molecules that present alternative topographies; these molecules are shown to be significantly less potent.

  DOI：

  10.1021/ja00091a008
• 作为产物：
  描述：

  2-氨基-5-碘苯甲酸 在 potassium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 5-iodo-N-methylisatoic anhydride
  参考文献：
  名称：

  Design, synthesis and biological evaluation of E-ring modified evodiamine derivatives as novel antitumor agents

  摘要：

  DOI：

  10.1016/j.cclet.2014.03.043

文献信息

• Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
  申请人：Allen R. Jennifer

  公开号：US20070249605A1

  公开（公告）日：2007-10-25

  This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one quinolone based compound. This invention further involves assays for the detection of a hydroxyproline residue in a HIF molecule.

  这项发明涉及一类新型的喹诺酮类化合物，这些化合物显示出脯氨酰羟化酶抑制活性。该发明还涉及通过向受试者施用至少一种喹诺酮类化合物，来提高受试者中的HIF水平或活性，或治疗与受试者中HIF水平或活性相关的病症的方法。此外，该发明还涉及用于检测HIF分子中羟基脯氨酸残基的试验方法。
• From Peptide to Non-Peptide. 3. Atropisomeric GPIIbIIIa Antagonists Containing the 3,4-Dihydro-1<i>H</i>-1,4-benzodiazepine-2,5-dione Nucleus
  作者：Brent K. Blackburn、Arthur Lee、Mark Baier、Benjamin Kohl、Alan G. Olivero、Regina Matamoros、Kirk D. Robarge、Robert S. McDowell

  DOI：10.1021/jm960652r

  日期：1997.2.1

  antagonists. Resolution of these antagonists was accomplished by the introduction of a tert-butyl group at N1 and a chlorine at C9 on the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus and enantiospecific substitution on the beta-alanine side chain attached to N4. The relative configuration was determined by single-crystal X-ray analysis. Further, conformational analyses using ab initio calculations were

  非肽GPIIbIIIa拮抗剂的苯并二氮杂二酮类经过修饰，可以分离非相互转化的旋转异构体或阻转异构体，目的是与含活性RGD的肽和其他非肽拮抗剂相比，检查它们的构效关系。这些拮抗剂的拆分是通过在3,4-二氢-1H-1,4-苯并二氮杂-2,5-二酮核上在N1处引入叔丁基和在C9处引入氯并在β上引入对映体特异性取代来实现的-连接至N4的-丙氨酸侧链。相对构型通过单晶X射线分析确定。此外，进行了使用从头算的构象分析，以评估有关β-丙氨酸侧链的构象偏好。数据支持在苯并二氮杂二酮类拮抗剂与在环状肽G4120中发现的RGD三肽序列的“杯状”呈递之间存在良好的地形相关性。讨论了这些化合物与其他肽类和非肽类拮抗剂之间的关系。
• Nickel‐Catalyzed Decarboxylative Cyclization of Isatoic Anhydrides with Carbodiimides: Synthesis of 2,3‐Dihydroquinazolin‐4(1 <i>H</i> )‐ones
  作者：Zhen Zhang、Ziqiang Qin、Wenxu Chang、Jiazhu Li、Ruoqian Fan、Xing Wu、Rongrong Guo、Xiangqi Xie、Lanxin Zhou

  DOI：10.1002/adsc.202000047

  日期：2020.7.29

  isatoic anhydrides with carbodiimides was developed. This protocol realized the direct introduction of carbodiimides into heterocyclic compounds under an in situ generated Ni(0) complex. Synthetically, this methodology provides a simplified and secure new approach for the preparation of 2‐imino‐2,3‐dihydroquinazolin‐4(1H )‐ones. The control experiments and DFT theoretical calculations indicated that

  在这项研究中，开发了使用碳二亚胺的镍催化的isatoic酸酐的脱羧环化反应。该协议实现了在原位生成的Ni（0）络合物下将碳二亚胺直接引入杂环化合物中。综合而言，该方法为制备2-亚氨基-2,3-二氢喹唑啉-4（1 H）-酮提供了一种简化且安全的新方法。控制实验和DFT理论计算表明，Ni（0）催化的过程对整个转化至关重要。
• Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b
  申请人：Genentech, Inc.

  公开号：US05663166A1

  公开（公告）日：1997-09-02

  A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

  提供一种苯二氮平二酮衍生物，其作为非肽血小板聚集抑制剂。该抑制剂强效抑制纤维蛋白原与GPII.sub.b III.sub.a受体的结合，并提供在治疗需要阻断血小板聚集的疾病的治疗组合物中。这些非肽抑制剂与溶栓剂和抗凝剂结合使用。
• QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF
  申请人：Allen Jennifer R.

  公开号：US20100184763A1

  公开（公告）日：2010-07-22

  This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one quinolone based compound. This invention further involves assays for the detection of a hydroxyproline residue in a HW molecule.

  本发明涉及一种新的基于喹诺酮的化合物，该化合物表现出脯氨酸羟化酶抑制活性。本发明还涉及通过向受试者施用至少一种基于喹诺酮的化合物来增加受试者中HIF水平或活性或治疗与HIF水平或活性相关的疾病的方法。本发明还涉及用于检测HW分子中羟基脯氨酸残基的测定方法。